Tablets & Capsules

TC0319

Issue link: https://www.e-digitaleditions.com/i/1087673

Contents of this Issue

Navigation

Page 28 of 51

Tablets & Capsules March 2019 27 3. Transfer team responsibilities In this case, the sending unit was not included, because the tech transfer wasn't collaborative between the two sites. We listed the following groups: technical development and process; quality assurance; quality con- trol; manufacturing; engineering; and health, safety, and environment. We also included the representatives assigned for each group, and they formed the core team. 4. Documents and information to be transferred We provided the receiving unit with the documents listed in Figure 2. In our case, it was a straightforward process using an active ingredient made specifically for the company and with history of sticking during com- pression. We made sure to include a CofA and specifica- tions from the active ingredient supplier (including the supplier item number) as well as the active ingredient characterization report (the supplier provided a specific particle size distribution). Because the active ingredient had a history of sticking issues, we made sure to include in the package not only the drawings of the tooling but also a copy of the order to the tooling manufacturer so that the receiving unit would know which coating or treatment was applied. (Don't assume that the tooling supplier will remain the same; it may change.) 5. Side-by-side comparison and risk assessment A side-by-side comparison, as shown in Figure 3, is a good way to visually compare the process at the sending unit with the proposed process at the receiving unit. Following the gap analysis and identification of risks from the potential and proposed changes between the sending and receiving units, we provided an initial risk assessment, as shown in Table 1. 6. Planned transfer activities Pilot batches. The company decided to perform a func- tionality characterization of the active ingredient and critical excipients, which involved manufacturing several small pilot batches to confirm the feasibility of compress- ing the product using the active and excipients that the receiving unit would be using. This step was essential because the product was a direct-compression tablet. We performed a first screening of the different active ingredient suppliers by testing different lots for chemical and physical characteristics (bulk and tapped density, particle size analysis, and flow properties). The technical group summarized these trials in a technical report, which should also document changes made to the com- pression tooling, if any. Stability batch. Based on the recommendations of the technical report, the company manufactured a stability batch, still at pilot scale, and issued a manufacturing/ packaging protocol and batch reports as well as a sta- bility protocol. Scale-up. As part of the transfer to the commercial-scale equipment, we evaluated and confirmed the critical pro- cess parameters and implemented in-process testing/con- trols during the stability batch. We issued a protocol and batch reports, which then served as a reference for the Check out Tablets & Capsules' article archive Looking for past articles? tabletscapsules.com (enter username & password or click register)

Articles in this issue

Links on this page

Archives of this issue

view archives of Tablets & Capsules - TC0319